BIEL BioElectronics Corp.

BioElectronics Announces U.S. FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain

BioElectronics Announces U.S. FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain

FREDERICK, MD, Feb. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioElectronics Corporation (OTC PINK: BIEL), , the maker of non-invasive electroceutical devices, is pleased to announce that it has obtained a new 510(k) clearance from the U.S. Food and Drug Administration (FDA). This new, over-the-counter marketing clearance was granted for the drug-free ActiPatch® medical device, for the indication: “adjunctive treatment of musculoskeletal pain.”

The ActiPatch was already FDA-cleared for over-the-counter treatment of pain from knee osteoarthritis and plantar fasciitis (heel pain) in 2017. The latest clearance expands these indications to cover all musculoskeletal pain complaints. Keith Nalepka, Vice President Sales and Marketing, expressed confidence on exploiting the expanded market opportunity: “The expanded clearance paves the way for new products to be marketed with approved medical claims for musculoskeletal pain, for instance, in the back, knee, hips, wrists, elbow, and ankle.”

Kelly Whelan, President of BioElectronics, stated: “The Company intends to capitalize on this new clearance by offering additional products to retail channel partners, in alignment with our 2020 strategy to prioritize the OEM (Original Equipment Manufacturer) aspects of our business.” With the latest clearance, ActiPatch remains the only pulsed shortwave therapy (PSWT) device with an over-the-counter clearance for treating any form of musculoskeletal pain.” 

The 510(k) application was prepared by the R&D team comprising: Kenneth McLeod, Ph.D., Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D., Gregory Mario and Jeremy Mario Professors, Duke University, Ian Rawe, Ph.D., Director of Clinical Research, BioElectronics and Sree Koneru, Ph.D., VP Product Development, BioElectronics.

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. 

For more information, please visit

Contact: Paul Knopick
 
940.262.3584
EN
03/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioElectronics Corp.

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of a Canine Arthr...

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study 96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via -- BioElectronics Corporation ( OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed ...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of Pilot Study Re...

BioElectronics Corporation Announces the Publication of Pilot Study Results Beneficial Treatment Effect for Phantom and Residual Limb Pain Identified FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. "Treating intractable postamputation pain with wearable, non-invasive, non-thermal, pulsed shortwave (radiofrequency) therapy: a randomized, double-ma...

 PRESS RELEASE

BioElectronics Chairman Updates Investors

BioElectronics Chairman Updates Investors Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.  As I have mentioned many times, I believe our strategic m...

 PRESS RELEASE

End of Year Message From the Chairman of the Board of BioElectronics

End of Year Message From the Chairman of the Board of BioElectronics FREDERICK, MD, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via – BioElectronics Corp. (OTC: BIEL) is pleased to provide this end of year message to investors, customers, suppliers and other partners. As described below, the last six months have produced mixed results. Research Update We have seen good progress on the research side. An investigator-sponsored study at University of California San Diego (UCSD) for phantom limb was completed this last fall and the paper is now under peer review for publication. All indications are ...

 PRESS RELEASE

BioElectronics’ Chairman Discusses Recent Clinical Research Findings

BioElectronics’ Chairman Discusses Recent Clinical Research Findings Company Receives Initial Purchase Order From Stada MENA FREDERICK, MD, July 22, 2022 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today announced via a Shareholder’s update that the Company has completed and undertaken additional clinical research and has received the initial stocking purchase order from its distribution partner, Stada.  The update is below: Dear Shareholders, I would like to take this opportunity to discuss some new developments and thei...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch